2 completed, 1 active not recruiting. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Zynerba Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE) ZYN002 - 22Q11.2 Deletion Syndrome | Phase 2 | Completed | Harmony Biosciences Management, Inc. | 20 | 2020-02-19 | 2026-03-09 |
| Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS ZYN002 - Cannabidiol Transdermal Gel - Fragile X Syndrome | Phase 2 / Phase 3 | Active not recruiting | Zynerba Pharmaceuticals, Inc. | 476 | 2018-11-09 | 2026-05-27 |
| Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) ZYN002 - Cannabidiol Transdermal Gel, Placebo Transdermal Gel - Fragile X Syndrome | Phase 2 / Phase 3 | Completed | Zynerba Pharmaceuticals, Inc. | 212 | 2018-06-12 | 2022-07-06 |
Fragile X Syndrome (2) · DiGeorge Syndrome (1)
Australia (3) · United States (3) · New Zealand (2) · United Kingdom (1)